SCHEMBL10136052

SCHEMBL10136052

CC(C)(C)OC(=O)NCC(=O)NCC(=O)NCC(=O)ON1C(=O)CCC1=O

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPFFR1 Q9GZQ6 1/20 0.39
NPFFR2 Q9Y5X5 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.38
ALDH1A1 P00352 3/20 0.36
KMT2A Q03164 3/20 0.36
MAPT P10636 2/20 0.36
HPGD P15428 2/20 0.36
KDM4E B2RXH2 2/20 0.36
LMNA P02545 2/20 0.36
GAA P10253 2/20 0.36
GLA P06280 1/20 0.36
CASP1 P29466 1/20 0.36
RAB9A P51151 1/20 0.36
CASP7 P55210 1/20 0.36
HSD17B10 Q99714 1/20 0.36
TSHR P16473 2/20 0.36
MEN1 O00255 2/20 0.36
EPHX2 P34913 1/20 0.36
SIGMAR1 Q99720 1/20 0.35
TDP1 Q9NUW8 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10046524 1.00 NPFFR1 (0.39) NPFFR1NPFFR2L3MBTL1ALDH1A1KMT2A
SCHEMBL242270 0.94 L3MBTL1 (0.41) L3MBTL1ALDH1A1KMT2AMAPTHPGD
SCHEMBL10046298 0.85 NPFFR1 (0.33) NPFFR1NPFFR2L3MBTL1ALDH1A1KMT2A
SCHEMBL19446136 0.83 NPFFR1 (0.32) NPFFR1NPFFR2L3MBTL1MAPTHPGD
SCHEMBL22005285 0.82 GAA (0.33) ALDH1A1KMT2AHPGDGAAMEN1
SCHEMBL22005196 0.82 RECQL (0.33) ALDH1A1HPGD
SCHEMBL15500314 0.82 NPFFR1 (0.32) NPFFR1NPFFR2L3MBTL1ALDH1A1KMT2A
SCHEMBL3122796 0.82 ALDH1A1 (0.44) L3MBTL1ALDH1A1KMT2AMAPTHPGD
SCHEMBL2734924 0.82 APLNR (0.36) L3MBTL1ALDH1A1KMT2AMAPTHPGD
SCHEMBL21862213 0.82 CTSS (0.52)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4426727-A2 SPECIFIC CONJUGATION OF AN ANTIBODY Hangzhou Dac Biotech Co., Ltd. (CN) 2024-09-11 EP disclosed
US-11732038-B2 Conjugates comprising cell-binding agents and cytotoxic agents IMMUNOGEN, INC. (US) 2023-08-22 US disclosed
US-11732038-B2 Conjugates comprising cell-binding agents and cytotoxic agents IMMUNOGEN, INC. (US) 2023-08-22 US disclosed
US-20230241241-A1 CONJUGATES OF A CELL-BINDING MOLECULE WITH CAMPTOTHECIN ANALOGS HANGZHOU DAC BIOTECH CO., LTD. (CN) 2023-08-03 US disclosed
US-20230241241-A1 CONJUGATES OF A CELL-BINDING MOLECULE WITH CAMPTOTHECIN ANALOGS HANGZHOU DAC BIOTECH CO., LTD. (CN) 2023-08-03 US disclosed
US-20220409734-A1 ANTIBODY DRUG CONJUGATES TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2022-12-29 US disclosed
WO-2022078524-A4 SPECIFIC CONJUGATION OF AN ANTIBODY HANGZHOU DAC BIOTECH CO., LTD. (CN) 2022-12-08 WO disclosed
WO-2022078524-A2 SPECIFIC CONJUGATION OF AN ANTIBODY HANGZHOU DAC BIOTECH CO., LTD. (CN) 2022-04-21 WO disclosed
US-20210299271-A1 CONJUGATES COMPRISING CELL-BINDING AGENTS AND CYTOTOXIC AGENTS IMMUNOGEN, INC. 2021-09-30 US disclosed
US-10988531-B2 Conjugates comprising cell-binding agents and cytotoxic agents IMMUNOGEN, INC. (US) 2021-04-27 US disclosed
US-20090131334-A1 ABUSE-RESISTANT AMPHETAMINE PRODRUGS SHIRE LLC (US) 2009-05-21 US disclosed
US-20090131322-A1 ABUSE-RESISTANT AMPHETAMINE PRODRUGS SHIRE LLC (US) 2009-05-21 US disclosed
US-20090131533-A1 ABUSE-RESISTANT AMPHETAMINE PRODRUGS SHIRE LLC (US) 2009-05-21 US disclosed
US-20090131325-A1 ABUSE-RESISTANT AMPHETAMINE PRODRUGS SHIRE LLC (US) 2009-05-21 US disclosed
US-20090131526-A1 ABUSE-RESISTANT AMPHETAMINE PRODRUGS SHIRE LLC (US) 2009-05-21 US disclosed
US-20090124831-A1 ABUSE-RESISTANT AMPHETAMINE PRODRUGS SHIRE LLC (US) 2009-05-14 US disclosed
US-7375083-B2 Pharmaceutical compositions for prevention of overdose or abuse SHIRE LLC (US) 2008-05-20 US disclosed
US-20080086016-A1 ABUSE RESISTANT LYSINE AMPHETAMINE COMPOUNDS NEW RIVER PHARMACEUTICALS INC. (US) 2008-04-10 US disclosed
US-7223735-B2 Abuse resistant lysine amphetamine compounds NEW RIVER PHARMACEUTICALS INC. (US) 2007-05-29 US disclosed
US-20070042955-A1 Abuse-resistant amphetamine prodrugs NEW RIVER PHARMACEUTICALS INC. (US) 2007-02-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090131533-A1 ABUSE-RESISTANT AMPHETAMINE PRODRUGS COMT, CYP3A5, CYP2D6 NPFFR1 1255/4885NPFFR2 1520/4885L3MBTL1 836/4885
US-20090131322-A1 ABUSE-RESISTANT AMPHETAMINE PRODRUGS COMT, CYP3A5, CYP2D6 NPFFR1 1255/4885NPFFR2 1520/4885L3MBTL1 836/4885
US-11732038-B2 Conjugates comprising cell-binding agents and cytotoxic agents PCNA, EPCAM, MKI67 NPFFR1 3897/4885NPFFR2 3815/4885L3MBTL1 1186/4885
US-20070042955-A1 Abuse-resistant amphetamine prodrugs COMT, CYP3A5, CYP2D6 NPFFR1 1255/4885NPFFR2 1520/4885L3MBTL1 836/4885
US-20090131526-A1 ABUSE-RESISTANT AMPHETAMINE PRODRUGS COMT, CYP3A5, CYP2D6 NPFFR1 1255/4885NPFFR2 1520/4885L3MBTL1 836/4885
US-10988531-B2 Conjugates comprising cell-binding agents and cytotoxic agents PCNA, EPCAM, MKI67 NPFFR1 3897/4885NPFFR2 3815/4885L3MBTL1 1186/4885
US-20220409734-A1 ANTIBODY DRUG CONJUGATES STING1, CGAS, TBK1 NPFFR1 3506/4885NPFFR2 3557/4885L3MBTL1 4082/4885
US-20090131325-A1 ABUSE-RESISTANT AMPHETAMINE PRODRUGS COMT, CYP3A5, CYP2D6 NPFFR1 1255/4885NPFFR2 1520/4885L3MBTL1 836/4885
US-20080086016-A1 ABUSE RESISTANT LYSINE AMPHETAMINE COMPOUNDS COMT, KDM6B, KDM5B NPFFR1 1716/4885NPFFR2 1857/4885L3MBTL1 258/4885
US-20090124831-A1 ABUSE-RESISTANT AMPHETAMINE PRODRUGS COMT, CYP3A5, CYP2D6 NPFFR1 1255/4885NPFFR2 1520/4885L3MBTL1 836/4885
US-20090131334-A1 ABUSE-RESISTANT AMPHETAMINE PRODRUGS COMT, CYP3A5, CYP2D6 NPFFR1 1255/4885NPFFR2 1520/4885L3MBTL1 836/4885
US-20210299271-A1 CONJUGATES COMPRISING CELL-BINDING AGENTS AND CYTOTOXIC AGENTS PCNA, EPCAM, MKI67 NPFFR1 3897/4885NPFFR2 3815/4885L3MBTL1 1186/4885
US-20230241241-A1 CONJUGATES OF A CELL-BINDING MOLECULE WITH CAMPTOTHECIN ANALOGS CD4, DCLRE1A, TOP1 NPFFR1 2923/4885NPFFR2 4109/4885L3MBTL1 18/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.